REFERENCES
- Meissner WA, Warren S. Tumours of the Thyroid Gland. Atlas of Tumor Pathology, Second Series, Fascicle 4. Washington, DC: Armed Forces Institute of Pathology; 1969.
- Napalkov NP. Experimental analysis of the relationship between endemic goitre and tumorous growth in the thyroid gland. Modern problems of oncology. Lenningrad. Patrov Inst Oncol; 1971.
- Proliferación celular y cáncer. Coordinadores: María Cascaels y Julio R. Villanueva. Edita: Fundación Científica de la AECC. 1994.
- Fernández-Santos JM, De Miguel M, González-Campora R, Salguero-Villadiego M, Cabrera JJ, Galera-Davidson H. Ki-ras mutational analysis in rat follicular-cell proliferative lesions of the thyroid gland induced by radioactive iodine and potassium perchlorate. J Endocrinol Invest 2004;27:12–17.
- Steward RD, Murray IP. An evaluation of the perchlorate discharge text. J Clin Endocrinol Metab 1966;26(10):1050–1058.
- Wang Y, Hou P, Yu H, . High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/akt pathway in thyroid tumours. J Clin Endocrinol Metab 2007;92:2387–2390.
- Fagin JA, Matsuo K, Karmakar A, . High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 1993;91:179–184.
- Farid NR. P53 mutations in thyroid carcinoma: tidings from an old foe. J Endocrinol Invest 2001;24:536–545.
- Mercer KE, Pritchard CA. Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta 2003;1653(1):25–40.
- Scheid MP, Woodgett JR. Phosphatidylinositol 3’ kinase signaling in mammary tumorigenesis. J Mammary Gland Biol Neoplasia 2001;6 (1):83–99.
- Duronio V, Scheid MP. Downstream signalling events regulated by phosphatidylinositol 3-kinase activity. Ettinger SCell Signal 1998;10(4):233–239.
- Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973–2002. J Am Med Assoc 2006;295(18):2164–216726.
- DeLellis RA, Lloyd RV, Heitz PU, Eng C, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Endocrine Organs. Lyon: IARC Press; 2004.
- Kobayashi Y, Kawaoi A, Katoh R. Mutation of ras oncogene in di-isopropanolnitrosamine-induced rat thyroid carcinogenesis. Virchows Arch 2002;441:289–295.
- Vitagliano D, Portella G, Troncone G, . Thyroid targeting of the N-ras (Gln61Lys) oncogene in transgenic mice results infollicular tumours that progress to poorly differentiated carcinomas. Oncogene 2006;25:5467–5474.
- Yeager N, Klein-Szanto A, Kimura S, Di Cristofano A. Pten loss in the mouse thyroid causes goitre and follicular adenomas: insights into thyroid function and Cowden disease pathogenesis. Cancer Res 2007;67:959–966.
- Hou P, Liu D, Shan Y, . Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res 2007;13:1161–1170.
- Trovisco V, Vieira de Castro I, Soares P, . BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J Pathol 2004;202(2):247–251.
- Nikiforova MN, Kimura ET, Gandhi M, . BRAF mutations in thyroid tumours are restricted to papillary carcinoma and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 2003;88:5399–5404.
- Fukushima T, Suzuki S, Mashiko M, . BRAF mutations in papillary carcinomas of the thyroid. Oncogene 2003;22(41):6455–6457.
- Xu X, Quiros RM, Gattuso P, . High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res 2003;63(15):4561–4567.
- Cohen Y, Xing M, Mambo E, . BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 2003;95(8):625–627.
- Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 2007;28(7):742–762.